NEW YORK, Feb. 4, 2025 /PRNewswire/ --  Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Regeneron and certai ...

Regeneron Pharmaceuticals, Inc. (REGN) reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi (SNY) for Dupixent, higher Eylea HD and L ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

On Tuesday, Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29.The company reported sales of $3.79 billion, up 10%, beating the consensus of $3.75 billion.“Regeneron’s financial and commercial strength allows for continued investment in our industry-leading R&D pipeline, while simultaneously returning capital to our shareholders through our newly initiated dividend program and increased share repurchase capacity,” said Leo ...

Regeneron (REGN) reported $3.79 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.3%. EPS of $12.07 for the same period compares to $11.86 a year ago.The reported revenue represents a surprise of +0.07% over the Zacks Consensus Estimate of $3.79 billion. With the consensus EPS estimate being $11.62, the EPS surprise was +3.87%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Regeneron (REGN) came out with quarterly earnings of $12.07 per share, beating the Zacks Consensus Estimate of $11.62 per share. This compares to earnings of $11.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.87%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $11.75 per share when it actually produced earnings of $12.46, delivering a surprise of 6.04%.Over the last four quarter ...

Exhibit 99.1 Press Release Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43 Annual J.P. Morgan Healthcare Conference Dupixent is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD and EYLEA remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudi ...

Fourth quarter 2024 revenues increased 10% to $3.79 billion versus fourth quarter 2023Full year 2024 revenues increased 8% to $14.20 billion versus 2023; excluding RonapreveTM(a)(b), revenues increased 10%Fourth quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 15% to $3.70 billion versus fourth quarter 2023; full year 2024 Dupixent global net sales increased 22% to $14.15 billion versus 2023Fourth quarter 2024 U.S. net sales for EYLEA HD® and EYLEA® increased 2% versus fourth quarter 2 ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=126299&from ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=126275&from=4 CLASS ...